Coya Therapeutics initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Coya Therapeutics with a Buy rating and $18 price target. Coya is an emerging biotech company focused on treating neurological conditions using novel immunomodulatory approaches, the analyst tells investors in a research note. The firm says Coya is developing proprietary products focused on the biology and potential therapeutic advantages of regulatory T cells to target systemic inflammation and neuroinflammation.